Ardelyx Inc. (ARDX) shares surged 6.92% in the pre-market trading session on Thursday, following the company's impressive fourth-quarter 2024 earnings results that surpassed analyst estimates.
The biopharmaceutical company reported quarterly earnings of $0.02 per share, beating the consensus estimate of $0.01 by 100%. This marked a significant improvement from the loss of $0.12 per share reported in the same period last year. Ardelyx's revenue for the quarter stood at $116.13 million, a remarkable 237.95% year-over-year increase, and also exceeded the analyst consensus estimate of $109.94 million by 5.63%.
The strong financial performance and better-than-expected results suggest that Ardelyx's products and pipeline are gaining traction, driving investor optimism and propelling the stock higher in the pre-market trading session.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。